Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 3,390,000 shares, a drop of 9.4% from the November 15th total of 3,740,000 shares. Based on an average daily volume of 761,800 shares, the days-to-cover ratio is currently 4.4 days.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research reports. Bank of America boosted their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. Raymond James lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research report on Monday, August 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares of the company's stock, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 over the last quarter. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Eventide Asset Management LLC grew its position in shares of Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock valued at $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock valued at $37,684,000 after buying an additional 135,829 shares during the period. AQR Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock worth $65,862,000 after buying an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $29,111,000. Finally, Avoro Capital Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock valued at $97,200,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ:ALNY traded up $0.18 during midday trading on Friday, reaching $245.44. The company had a trading volume of 592,047 shares, compared to its average volume of 860,965. The stock has a market capitalization of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. The stock's fifty day moving average price is $267.01 and its 200-day moving average price is $249.57. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals's quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.